This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Sesen Bio Past Earnings Performance
Past criteria checks 0/6
Key information
18.7%
Earnings growth rate
38.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 75.1% |
| Return on equity | -12.6% |
| Net Margin | -49.7% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Sesen Bio and Carisma Therapeutics announce merger agreement
Sep 21Sesen Bio GAAP EPS of -$0.16 misses by $0.03
Aug 08Sesen Bio granted additional time period for regaining compliance
Jul 27Sesen Bio slips after decision to pause U.S. studies for lead asset
Jul 18Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
Jun 02We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Sesen Bio: Interesting Price Drop After CRL
Nov 24Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Nov 17Sesen Bio: The Road Ahead
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00
Aug 12Sesen Bio: Binary Event Approaching
Jun 13Sesen Bio inks global supply partnership with Qilu Pharmaceutical
Jun 02Sesen Bio EPS misses by $0.27
May 10Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
May 07News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat
Feb 18Sesen announces positive FDA meeting for vicineum's marketing application
Feb 01Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Sesen Bio/Qilu Pharma's Vicineum IND application accepted for review in China
Jan 13Sesen Bio files US application for its Vicineum in bladder cancer
Dec 21Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook
Dec 21
Sesen Bio: A Look At Vicineum's Potential
Nov 29Sesen Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 09Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Sesen Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 40 | -20 | 40 | 37 |
| 30 Sep 22 | 60 | -3 | 41 | 19 |
| 30 Jun 22 | 20 | 48 | 42 | 0 |
| 31 Mar 22 | 22 | 54 | 33 | 0 |
| 31 Dec 21 | 27 | 0 | 29 | 24 |
| 30 Sep 21 | 7 | -24 | 24 | 18 |
| 30 Jun 21 | 18 | -118 | 20 | 0 |
| 31 Mar 21 | 16 | -119 | 16 | 0 |
| 31 Dec 20 | 11 | -23 | 14 | 29 |
| 30 Sep 20 | 11 | -41 | 14 | 0 |
| 30 Jun 20 | 0 | -32 | 13 | 0 |
| 31 Mar 20 | 0 | -60 | 13 | 0 |
| 31 Dec 19 | 0 | -107 | 12 | 0 |
| 30 Sep 19 | 0 | -81 | 12 | 0 |
| 30 Jun 19 | 0 | -82 | 13 | 0 |
| 31 Mar 19 | 0 | -36 | 13 | 0 |
| 31 Dec 18 | 0 | -34 | 12 | 0 |
| 30 Sep 18 | 0 | -33 | 10 | 0 |
| 30 Jun 18 | 0 | -29 | 8 | 0 |
| 31 Mar 18 | 0 | -27 | 8 | 0 |
| 31 Dec 17 | 0 | -29 | 8 | 0 |
| 30 Sep 17 | 1 | -26 | 6 | 0 |
| 30 Jun 17 | 30 | 3 | 10 | 0 |
| 31 Mar 17 | 30 | 3 | 12 | 0 |
| 31 Dec 16 | 30 | 2 | 11 | 0 |
| 30 Sep 16 | 30 | -5 | 14 | 0 |
| 30 Jun 16 | 1 | -34 | 11 | 0 |
| 31 Mar 16 | 1 | -35 | 9 | 0 |
Quality Earnings: SESN is currently unprofitable.
Growing Profit Margin: SESN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SESN is unprofitable, but has reduced losses over the past 5 years at a rate of 18.7% per year.
Accelerating Growth: Unable to compare SESN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SESN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.2%).
Return on Equity
High ROE: SESN has a negative Return on Equity (-12.57%), as it is currently unprofitable.